About Intra-Cellular Therapies (NASDAQ:ITCI)
Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Lumateperone (also known as ITI-007) is its lead product candidate. The Company's bipolar depression program consists of two Phase III multi-center, randomized, double-blind, placebo-controlled clinical trials: one to evaluate lumateperone as a monotherapy and the other to evaluate lumateperone as an adjunctive therapy with lithium or valproate. The Company initiated Phase III development of lumateperone for the treatment of agitation in patients with dementia, including Alzheimer's Disease (AD).
Industry, Sector and Symbol
Trailing P/E Ratio-10.9056603773585
Forward P/E Ratio-6.94
Sales & Book Value
Price / Sales5,056.81
Price / CashN/A
Book Value$8.33 per share
Price / Book2.78
Return on Equity-26.67%
Return on Assets-25.60%
Intra-Cellular Therapies (NASDAQ:ITCI) Frequently Asked Questions
What is Intra-Cellular Therapies' stock symbol?
Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."
How were Intra-Cellular Therapies' earnings last quarter?
Intra-Cellular Therapies Inc (NASDAQ:ITCI) posted its quarterly earnings data on Thursday, March, 1st. The biopharmaceutical company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.06. The biopharmaceutical company had revenue of $5.06 million for the quarter, compared to the consensus estimate of $0.05 million. Intra-Cellular Therapies had a negative return on equity of 26.67% and a negative net margin of 39,745.53%. The company's revenue was down 94.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.64) EPS. View Intra-Cellular Therapies' Earnings History.
When will Intra-Cellular Therapies make its next earnings announcement?
Where is Intra-Cellular Therapies' stock going? Where will Intra-Cellular Therapies' stock price be in 2018?
11 brokerages have issued 1 year price objectives for Intra-Cellular Therapies' shares. Their forecasts range from $12.00 to $36.00. On average, they anticipate Intra-Cellular Therapies' stock price to reach $27.80 in the next twelve months. View Analyst Ratings for Intra-Cellular Therapies.
What are Wall Street analysts saying about Intra-Cellular Therapies stock?
Here are some recent quotes from research analysts about Intra-Cellular Therapies stock:
- 1. According to Zacks Investment Research, "Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York. " (3/6/2018)
- 2. Cantor Fitzgerald analysts commented, "Lumateperone NDA filing still expected in mid-2018. We view the pre- NDA meeting (and what may be said thereafter), the actual filing and the FDA acceptance of it (presumably) as minor events that are expected and not stock moving." (3/1/2018)
- 3. SunTrust Banks, Inc. analysts commented, "Meeting with FDA could help identify the path forward for ralinepag. On the 3Q17 results conference call, management commented that the company will seek a meeting with the FDA to determine the pivotal development plan for ralinepag. Specific timing of the meeting is pending FDA scheduling but management laid out their views on the drug candidate’s development program. Key considerations include 1) accelerating time to market, 2) maximizing the breadth and scope of label, 3) raising physician awareness of the compound and 4) comparing ralinepag with other available treatments." (11/8/2017)
Who are some of Intra-Cellular Therapies' key competitors?
Some companies that are related to Intra-Cellular Therapies include arGEN-X BV (ARGX), Immunomedics (IMMU), Emergent Biosolutions (EBS), Ultragenyx Pharmaceutical (RARE), Spark Therapeutics (ONCE), Horizon Pharma (HZNP), The Medicines (MDCO), Crispr Therapeutics (CRSP), Akorn (AKRX), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Aerie Pharmaceuticals (AERI), Portola Pharmaceuticals (PTLA), Myriad Genetics (MYGN), Corcept Therapeutics (CORT), Akcea Therapeutics (AKCA), Motif Bio (MTFB) and Sangamo Therapeutics (SGMO).
Who are Intra-Cellular Therapies' key executives?
Intra-Cellular Therapies' management team includes the folowing people:
- Lawrence J. Hineline CPA, Chief Financial Officer, Vice President - Finance, Treasurer, Assistant Secretary (Age 60)
- Andrew Satlin, Executive Vice President and Chief Medical Officer
- Robert E. Davis Ph.D., Senior Vice President and Chief Scientific Officer (Age 66)
- Michael I. Halstead, Senior Vice President, General Counsel, Secretary (Age 44)
- Kimberly E. Vanover Ph.D., Senior Vice President, Clinical Development (Age 51)
- Juan F. Sanchez M.D., Vice President - Corporate Communications (Age 44)
- Sharon Mates Ph.D., Chairman of the Board, President, Chief Executive Officer (Age 64)
- Christopher D. Alafi Ph.D., Independent Director (Age 53)
- Richard Alan Lerner M.D., Independent Director (Age 78)
- Joel S. Marcus J.D. CPA, Independent Director (Age 69)
Has Intra-Cellular Therapies been receiving favorable news coverage?
Media coverage about ITCI stock has trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Intra-Cellular Therapies earned a daily sentiment score of 0.03 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 45.99 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are Intra-Cellular Therapies' major shareholders?
Intra-Cellular Therapies' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.33%), Wasatch Advisors Inc. (3.53%), Millennium Management LLC (2.67%), Deutsche Bank AG (1.43%), Renaissance Technologies LLC (1.05%) and Geode Capital Management LLC (0.74%). Company insiders that own Intra-Cellular Therapies stock include Alafi Capital Co Llc, Christopher D Alafi, Kimberly E Vanover, Lawrence J Hineline, Michael Halstead, Richard A Lerner, Robert E Davis and Sharon Mates. View Institutional Ownership Trends for Intra-Cellular Therapies.
Which institutional investors are selling Intra-Cellular Therapies stock?
ITCI stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Goldman Sachs Group Inc., Wasatch Advisors Inc., C WorldWide Group Holding A S, Wells Fargo & Company MN, Metropolitan Life Insurance Co. NY, Alliancebernstein L.P. and C M Bidwell & Associates Ltd.. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Kimberly E Vanover, Lawrence J Hineline, Michael Halstead, Richard A Lerner, Robert E Davis and Sharon Mates. View Insider Buying and Selling for Intra-Cellular Therapies.
Which institutional investors are buying Intra-Cellular Therapies stock?
ITCI stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Renaissance Technologies LLC, Two Sigma Investments LP, Deutsche Bank AG, Candriam Luxembourg S.C.A., Schwab Charles Investment Management Inc. and TIAA CREF Investment Management LLC. Company insiders that have bought Intra-Cellular Therapies stock in the last two years include Alafi Capital Co Llc and Christopher D Alafi. View Insider Buying and Selling for Intra-Cellular Therapies.
How do I buy shares of Intra-Cellular Therapies?
Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intra-Cellular Therapies' stock price today?
One share of ITCI stock can currently be purchased for approximately $23.12.
How big of a company is Intra-Cellular Therapies?
Intra-Cellular Therapies has a market capitalization of $1.31 billion and generates $250,000.00 in revenue each year. The biopharmaceutical company earns $-97,770,000.00 in net income (profit) each year or ($2.12) on an earnings per share basis. Intra-Cellular Therapies employs 49 workers across the globe.
How can I contact Intra-Cellular Therapies?
Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-923-3344.
MarketBeat Community Rating for Intra-Cellular Therapies (ITCI)MarketBeat's community ratings are surveys of what our community members think about Intra-Cellular Therapies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Intra-Cellular Therapies (NASDAQ:ITCI) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.91||2.90||2.89||2.78|
|Ratings Breakdown: ||0 Sell Rating(s)|
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$27.80||$27.44||$26.75||$29.00|
|Price Target Upside: ||20.24% upside||67.45% upside||79.53% upside||35.58% upside|
Intra-Cellular Therapies (NASDAQ:ITCI) Consensus Price Target History
Intra-Cellular Therapies (NASDAQ:ITCI) Analyst Ratings History
(Data available from 3/20/2016 forward)
Intra-Cellular Therapies (NASDAQ:ITCI) Earnings History and Estimates Chart
Intra-Cellular Therapies (NASDAQ ITCI) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/9/2018|| || || || || || || || |
|3/1/2018||n/a||($0.50)||($0.56)||$0.05 million||$5.06 million||View||N/A|
|11/8/2017||Q3 2017||($0.53)||($0.53)||$0.06 million||$0.03 million||View||N/A|
|8/9/2017||Q2 2017||($0.74)||($0.41)||$0.03 million||$0.11 million||View||N/A|
|5/10/2017||Q1 2017||($0.74)||($0.62)||$0.02 million||$0.10 million||View||N/A|
|3/1/2017||Q4 2016||($0.77)||($0.64)||$0.10 million||$0.10 million||View||Listen|
|11/9/2016||Q316||($0.84)||($0.70)||$0.04 million||$4.36 million||View||Listen|
|8/4/2016||Q216||($0.79)||($0.71)||$0.02 million||$0.23 million||View||N/A|
|2/25/2016||Q415||($0.84)||($0.67)||$0.05 million||$30.66 million||View||Listen|
|8/5/2015||Q215||($0.72)||($0.61)||$40.00 million||$57.40 million||View||N/A|
|3/12/2015||Q4 2014||($0.49)||($0.52)||$0.07 million||View||N/A|
|5/5/2014||Q1 2014||($0.23)||($0.17)||$0.17 million||View||N/A|
|3/26/2014||($0.41)||($0.36)||$0.60 million||$0.83 million||View||N/A|
|11/5/2013||Q3 2013||($0.23)||($0.42)||$0.67 million||View||N/A|
Intra-Cellular Therapies (NASDAQ:ITCI) Earnings Estimates
2018 EPS Consensus Estimate: ($2.70)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Intra-Cellular Therapies (NASDAQ:ITCI)
No dividend announcements for this company have been tracked by MarketBeat.com
Intra-Cellular Therapies (NASDAQ ITCI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 21.00%
Institutional Ownership Percentage: 70.47%
Intra-Cellular Therapies (NASDAQ ITCI) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|2/16/2018||Lawrence J Hineline||VP||Sell||49,700||$20.02||$994,994.00|| |
|1/22/2018||Michael Halstead||SVP||Sell||25,500||$18.03||$459,765.00||191|| |
|1/8/2018||Kimberly E Vanover||SVP||Sell||772||$17.46||$13,479.12||12,373|| |
|1/8/2018||Sharon Mates||Chairman||Sell||6,604||$17.48||$115,437.92||1,088,707|| |
|1/5/2018||Kimberly E Vanover||SVP||Sell||1,185||$17.37||$20,583.45||26,803|| |
|1/5/2018||Sharon Mates||Chairman||Sell||11,257||$17.08||$192,269.56||1,099,964|| |
|1/4/2018||Lawrence J Hineline||CFO||Sell||3,192||$15.67||$50,018.64||68,686|| |
|12/29/2017||Christopher D Alafi||Director||Buy||1,001||$14.48||$14,494.48|| |
|12/11/2017||Richard A Lerner||Director||Sell||7,000||$15.09||$105,630.00||8,621|| |
|12/5/2017||Robert E Davis||SVP||Sell||650||$15.00||$9,750.00||28,514|| |
|11/22/2017||Christopher D Alafi||Director||Buy||10,000||$15.55||$155,500.00||744,466|| |
|10/30/2017||Sharon Mates||CEO||Sell||18,750||$15.75||$295,312.50||1,107,457|| |
|10/2/2017||Alafi Capital Co Llc||Major Shareholder||Buy||258,065||$15.50||$4,000,007.50||3,953,270|| |
|1/5/2017||Lawrence J Hineline||VP||Sell||1,918||$16.58||$31,800.44||63,389|| |
|1/5/2017||Michael Halstead||SVP||Sell||1,601||$16.55||$26,496.55||21,506|| |
|1/5/2017||Sharon Mates||Chairman||Sell||4,081||$16.55||$67,540.55||1,088,707|| |
|12/15/2016||Kimberly E Vanover||SVP||Sell||9,375||$15.23||$142,781.25||5,000|| |
|12/7/2016||Alafi Capital Co Llc||Major Shareholder||Buy||65,000||$16.27||$1,057,550.00||3,674,379|| |
|11/14/2016||Christopher D Alafi||Director||Buy||34,000||$14.50||$493,000.00||730,529|| |
|2/29/2016||Christopher D Alafi||Director||Buy||100,000||$29.70||$2,970,000.00||728,828|| |
|12/15/2015||Lawrence J. Hineline||CFO||Sell||45,000||$51.45||$2,315,250.00||62,200|| |
|12/11/2015||Sharon Mates||CEO||Sell||51,500||$53.87||$2,774,305.00||1,086,185|| |
|12/8/2015||Joel S Marcus||Director||Sell||92,700||$54.47||$5,049,369.00||18,722|| |
|11/24/2015||Lawrence J Hineline||CFO||Sell||5,000||$55.00||$275,000.00||59,700|| |
|6/8/2015||Lawrence P Wennogle||VP||Sell||25,000||$26.84||$671,000.00|| |
|3/11/2015||Christopher D Alafi||Director||Buy||625,000||$24.00||$15,000,000.00|| |
|12/9/2014||Lawrence J Hineline||CFO||Sell||22,500||$16.71||$375,975.00|| |
|12/1/2014||Moshe Alafi||Major Shareholder||Buy||1,422||$14.75||$20,974.50|| |
|11/28/2014||Christopher D Alafi||Director||Buy||35,000||$14.75||$516,250.00|| |
|11/19/2014||Alafi Capital Co Llc||Major Shareholder||Buy||1,034||$14.25||$14,734.50|| |
|11/18/2014||Alafi Capital Co Llc||Major Shareholder||Buy||3,664||$14.26||$52,248.64|| |
|11/13/2014||Alafi Capital Co Llc||Major Shareholder||Buy||12,200||$15.34||$187,148.00|| |
|11/6/2014||Michael Halstead||SVP||Buy||20,000||$15.38||$307,600.00|| |
|10/15/2014||Lawrence P Wennogle||VP||Sell||3,604||$15.00||$54,060.00|| |
|10/13/2014||Lawrence P Wennogle||VP||Sell||1,600||$15.00||$24,000.00|| |
|10/8/2014||Lawrence P Wennogle||VP||Sell||4,745||$15.00||$71,175.00|| |
|10/6/2014||Lawrence P Wennogle||VP||Sell||16,499||$15.00||$247,485.00|| |
|9/15/2014||Lawrence P Wennogle||VP||Sell||5,000||$15.00||$75,000.00|| |
|9/8/2014||Lawrence J Hineline||CFO||Sell||300||$15.00||$4,500.00|| |
|5/22/2014||Lawrence P Wennogle||VP||Sell||6,000||$15.00||$90,000.00|| |
Intra-Cellular Therapies (NASDAQ ITCI) News Headlines
|Intra-Cellular Therapies Inc (ITCI) Given Consensus Rating of "Buy" by Brokerages|
www.americanbankingnews.com - March 17 at 7:38 PM
|Intra-Cellular Therapies (ITCI) Lifted to Buy at BidaskClub|
www.americanbankingnews.com - March 17 at 5:36 PM
|Wired News – FDA Approved Intra-Cellular’s Rolling NDA Submission for Lumateperone for Schizophrenia|
finance.yahoo.com - March 15 at 8:33 AM
|Intra-Cellular Therapies (ITCI) Announces Positive Pre-NDA Meeting with FDA for Lumateperone|
www.streetinsider.com - March 13 at 7:05 PM
|Canaccord Genuity Reiterates $31.00 Price Target for Intra-Cellular Therapies (ITCI)|
www.americanbankingnews.com - March 13 at 3:46 PM
|Intra-Cellular Therapies (ITCI) Announces Positive Pre-NDA Meeting with FDA for Lumateperone - StreetInsider.com|
www.streetinsider.com - March 13 at 8:43 AM
|Intra-Cellular Therapies Announces Positive Pre-NDA Meeting with FDA for Lumateperone for the Treatment of Schizophrenia|
finance.yahoo.com - March 13 at 8:43 AM
|Intra-Cellular Therapies (ITCI) Upgraded at ValuEngine|
www.americanbankingnews.com - March 11 at 2:23 PM
|Intra-Cellular Therapies Inc Forecasted to Earn FY2018 Earnings of ($3.95) Per Share (ITCI)|
www.americanbankingnews.com - March 7 at 11:51 AM
|Intra-Cellular Therapies' (ITCI) "Outperform" Rating Reaffirmed at Leerink Swann|
www.americanbankingnews.com - March 7 at 10:59 AM
|Intra-Cellular Therapies Inc (ITCI) Expected to Earn Q1 2018 Earnings of ($0.62) Per Share|
www.americanbankingnews.com - March 7 at 7:55 AM
|Equities Analysts Set Expectations for Intra-Cellular Therapies Inc's FY2019 Earnings (ITCI)|
www.americanbankingnews.com - March 6 at 2:25 PM
|SunTrust Banks Weighs in on Intra-Cellular Therapies Inc's FY2022 Earnings (ITCI)|
www.americanbankingnews.com - March 5 at 9:50 AM
|Intra-Cellular Therapies Inc to Post Q1 2018 Earnings of ($0.62) Per Share, Leerink Swann Forecasts (ITCI)|
www.americanbankingnews.com - March 5 at 2:08 AM
|Intra-Cellular Therapies (ITCI) Given Buy Rating at Cowen|
www.americanbankingnews.com - March 3 at 8:22 PM
|Intra-Cellular Therapies (ITCI) Rating Reiterated by SunTrust Banks|
www.americanbankingnews.com - March 2 at 4:22 PM
|Intra-Cellular Therapies' (ITCI) Buy Rating Reiterated at Cantor Fitzgerald|
www.americanbankingnews.com - March 1 at 8:13 PM
|Intra-Cellular Therapies (ITCI) Announces Quarterly Earnings Results, Misses Estimates By $0.06 EPS|
www.americanbankingnews.com - March 1 at 1:56 PM
|Intra-Cellular Therapies reports Q4 results|
seekingalpha.com - March 1 at 9:43 AM
|Intra-Cellular Therapies (ITCI) Now Covered by JPMorgan Chase & Co.|
www.americanbankingnews.com - February 26 at 2:20 PM
|Intra-Cellular Therapies (ITCI) Scheduled to Post Earnings on Thursday|
www.americanbankingnews.com - February 23 at 5:26 PM
|Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call and Webcast|
finance.yahoo.com - February 22 at 8:34 AM
|Intra-Cellular Therapies Inc (ITCI) Receives Average Rating of "Buy" from Analysts|
www.americanbankingnews.com - February 20 at 7:46 PM
|Lawrence J. Hineline Sells 49,700 Shares of Intra-Cellular Therapies Inc (ITCI) Stock|
www.americanbankingnews.com - February 20 at 6:40 PM
|Intra-Cellular Therapies (ITCI) Upgraded to Sell by BidaskClub|
www.americanbankingnews.com - February 19 at 3:56 PM
|UPDATE - Intra-Cellular Therapies to Present at RBC Capital Markets 2018 Global Healthcare Conference|
finance.yahoo.com - February 15 at 5:10 PM
|Intra-Cellular Therapies (ITCI) Now Covered by Royal Bank of Canada|
www.americanbankingnews.com - February 11 at 3:24 PM
|Intra-Cellular Therapies to Present at Upcoming Investor Conferences|
finance.yahoo.com - February 7 at 9:52 AM
|Intra-Cellular Therapies (ITCI) Cut to "Strong Sell" at BidaskClub|
www.americanbankingnews.com - February 3 at 2:44 PM
|Financial Contrast: Intra-Cellular Therapies (ITCI) and Mast Therapeutics (SVRA)|
www.americanbankingnews.com - February 3 at 1:12 AM
|Intra-Cellular Therapies Inc (ITCI) Short Interest Update|
www.americanbankingnews.com - January 27 at 2:32 AM
|Intra-Cellular Therapies Inc (ITCI) Given Consensus Recommendation of "Buy" by Analysts|
www.americanbankingnews.com - January 26 at 7:28 PM
|Michael Halstead Sells 25,500 Shares of Intra-Cellular Therapies Inc (ITCI) Stock|
www.americanbankingnews.com - January 24 at 9:08 PM
|Stock Review for Biotech's Investors -- Inovio Pharma, Insmed, Intra-Cellular Therapies, and Jazz Pharma|
www.bizjournals.com - January 22 at 9:22 AM
|Intra-Cellular Therapies (ITCI) Upgraded by Zacks Investment Research to Buy|
www.americanbankingnews.com - January 20 at 12:33 PM
|Investors Purchase High Volume of Intra-Cellular Therapies Put Options (ITCI)|
www.americanbankingnews.com - January 19 at 3:10 AM
|Intra-Cellular Therapies (ITCI) Lowered to "Hold" at Zacks Investment Research|
www.americanbankingnews.com - January 14 at 8:10 PM
|Intra-Cellular Therapies (ITCI) Raised to Buy at Zacks Investment Research|
www.americanbankingnews.com - January 13 at 7:14 PM
|Intra-Cellular Therapies Inc. (ITCI) Chairman Sharon Mates Sells 6,604 Shares|
www.americanbankingnews.com - January 10 at 10:00 PM
|Kimberly E. Vanover Sells 772 Shares of Intra-Cellular Therapies Inc. (ITCI) Stock|
www.americanbankingnews.com - January 10 at 10:00 PM
|Newman Ferrara LLP Announces Corporate Governance Investigation of Intra-Cellular Therapies, Inc. - ITCI - Business Wire (press release)|
www.businesswire.com - January 10 at 3:29 PM
|Newman Ferrara LLP Announces Corporate Governance Investigation of Intra-Cellular Therapies, Inc. - ITCI|
finance.yahoo.com - January 10 at 3:29 PM
|Intra-Cellular Therapies Inc. (ITCI) to Post FY2019 Earnings of ($1.89) Per Share, Leerink Swann Forecasts|
www.americanbankingnews.com - January 8 at 5:40 PM
|BidaskClub Upgrades Intra-Cellular Therapies (ITCI) to Sell|
www.americanbankingnews.com - January 6 at 12:48 AM
|Lawrence J. Hineline Sells 3,192 Shares of Intra-Cellular Therapies Inc. (ITCI) Stock|
www.americanbankingnews.com - January 5 at 9:12 PM
|Kimberly E. Vanover Sells 1,185 Shares of Intra-Cellular Therapies Inc. (ITCI) Stock|
www.americanbankingnews.com - January 5 at 9:12 PM
|Intra-Cellular Therapies Inc. (ITCI) Chairman Sells $192,269.56 in Stock|
www.americanbankingnews.com - January 5 at 9:10 PM
|Intra-Cellular Therapies Inc. (ITCI) Director Christopher D. Alafi Buys 1,001 Shares|
www.americanbankingnews.com - January 3 at 7:52 PM
|Intra-Cellular Therapies to Present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)|
globenewswire.com - January 2 at 10:16 AM
|Intra-Cellular Therapies (ITCI) Downgraded by ValuEngine|
www.americanbankingnews.com - January 1 at 8:14 PM
Intra-Cellular Therapies (NASDAQ:ITCI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Intra-Cellular Therapies (NASDAQ:ITCI) Income Statement, Balance Sheet and Cash Flow Statement
Intra-Cellular Therapies (NASDAQ ITCI) Stock Chart for Tuesday, March, 20, 2018